A medical oncologist, Silvia Stacchiotti has a life-time professional dedication to patient care and research in bone and soft tissue sarcoma (STS), and gastrointestinal stromal tumor (GIST). She works in the Adult Mesenchymal and Rare Tumor Medical Treatment Unit, Cancer Medicine Department. at the Fondazione IRCCS Istituto Nazionale Tumori (Milan, Italy) where she is involved in all institutional research activities on sarcoma, with a special focus on ultra-rare sarcomas. Her works focuses on the identification of new treatments and treatment modalities for adult patients affected by sarcomas, starting from the localized to the advanced phase of disease. As sarcomas are rare tumors and the sarcoma family comprises >80 different histologies, over the last 20 years she has been working in collaboration with the Institutional groups and the international sarcoma community and patient advocates to improve cure and care of selected sarcoma types through 1) description of the natural history and sensitivity to conventional agents available for treatment of sarcoma; 2) identification of new targets, mechanisms of resistance and anticancer agents, 3) design of prospective clinical trials, 4) coordination of consensus meetings with the community of experts to draft clinical guidelines on the best approach to each sarcoma type; 5) interaction with the regulators (FDA; EMA) to help the approval of new drugs for sarcoma patients; 6) build prospective registries / observational studies. She is the current president of the Italian Sarcoma Group (ISG), the Italian scientific society for research and care of all ages sarcoma patients, and the current treasurer of the Connective Tissue Oncology Society (CTOS), the international scientific society for sarcomas. She is the faculty coordinator of the Sarcoma group of the European Society for Medical Oncology (ESMO) and the subject editor of the ESMO guidelines committee for sarcoma and GIST. She is the chair of the systemic therapy subcommittee of the EORTC Soft Tissue and Bone Sarcoma Group. She is included in the list of European Medical Agency (EMA) external experts. She is member of the advisory boards of Alleanza Contro il Cancro (ACC) and of the Federazione Italiana Gruppi Cooperativi (FICOG). She collaborates with several sarcoma Patient Advocacy Groups (PAG), among which the Chordoma Foundation, the Epithelioid Haemangioendothelioma (EHE) Rare Cancer Charity UK (EHERCC) the EHE Foundation US, the Desmoid Tumor Research Foundation, the Leiomyosarcoma Foundation, in which she serves as a member of the corresponding medical advisory boards. She is the Principal Investigator of several trials on sarcoma. She has authored >210 scientific publications (H Index 55).
Born in 1968, dr Silvia Stacchiotti received his medical degree in 1993 in Milan, and trained at the INT. She is certified in Clinical Oncology. She has four children.